A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2017
At a glance
- Drugs MOR 208 (Primary) ; Lenalidomide
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms L-MIND
- Sponsors MorphoSys
- 05 Dec 2017 According to a MorphoSys AG media release, data from this trial will be presented and discussed during an Investor and Analyst call on December 12, 2017.
- 05 Dec 2017 Planned End Date changed from 1 Sep 2019 to 1 Nov 2022.
- 05 Dec 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History